22:14 , Jan 31, 2019 |  BC Extra  |  Company News

J&J, MeiraGTx partner on gene therapies for rare retinal diseases

Janssen Pharmaceuticals Inc. picked up its first clinical gene therapies Thursday in a worldwide licensing deal with MeiraGTx Holdings plc (NASDAQ:MGTX) for rare inherited retinal disease therapies. MeiraGTx added $2.84 (30%) to $12.38 on Thursday....
19:32 , Dec 14, 2018 |  BC Week In Review  |  Company News

Biogen returns gene therapies to AGTC on lack of clinical activity

Applied Genetic Technologies Corp. (NASDAQ:AGTC) said late Dec. 12 that Biogen Inc. (NASDAQ:BIIB) terminated the companies’ gene therapy collaboration, leaving behind a partnership originally established to help Biogen build its gene therapy expertise. AGTC was...
23:34 , Dec 13, 2018 |  BC Extra  |  Company News

Biogen returns gene therapies to AGTC on lack of clinical activity

Applied Genetic Technologies Corp. (NASDAQ:AGTC) said late Wednesday that Biogen Inc. (NASDAQ:BIIB) terminated the companies’ gene therapy collaboration, leaving behind a partnership originally established to help Biogen build its gene therapy expertise. AGTC was down...
19:09 , May 18, 2018 |  BC Week In Review  |  Financial News

MeiraGTx proposes $86.3M IPO

MeiraGTx Holdings plc (New York, N.Y.) proposed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Barclays, Evercore ISI and Chardan. The company is developing a portfolio of...
22:17 , May 15, 2018 |  BC Extra  |  Financial News

MeiraGTx plans IPO

MeiraGTx Holdings plc (New York, N.Y.) proposed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Barclays, Evercore ISI and Chardan. The company is developing a portfolio of...
07:00 , Sep 13, 2016 |  BC Extra  |  Clinical News

Applied Genetic slides after clinical updates

Applied Genetic Technologies Corp. (NASDAQ:AGTC) fell $4.19 (32%) to $9 on Tuesday after it said enrollment was slower than expected in two Phase I/II studies of its ocular gene therapy candidates. One of the studies...
07:00 , May 18, 2015 |  BC Week In Review  |  Clinical News

Applied Genetic Technologies, Pfizer preclinical data

In dogs with achromatopsia, AAV-hCNGB3 led to functional rescue of cone cells in 100% of treated eyes. The product is an adeno-associated virus (AAV) vector expressing the human cyclic nucleotide gated channel beta 3 (CNGB3)...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Company News

Applied Genetic Technologies, Icagen deal

Applied Genetic Technologies received rights to Icagen patents related to the ion channel gene cyclic nucleotide gated channel beta 3 (CNGB3) . Applied Genetic Technologies will use the technology for gene therapies to treat achromtopsia,...